Introduction of imatinib (IM) and other tyrosine kinase inhibitors (TKIs) has radically improved the outcome of patients with CML and some other diseases with BCR/ABL expression. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.